医学研究与教育 ›› 2020, Vol. 37 ›› Issue (3): 39-43.DOI: 10.3969/j.issn.1674-490X.2020.03.006

• 临床医学 • 上一篇    下一篇

艾司西酞普兰合并托吡酯治疗男性酒依赖伴焦虑抑郁及复饮

韩笑1,2,张萍2,严保平2,崔彦龙2,曹志然1   

  1. 1.河北大学基础医学院, 河北 保定 071000;
    2.河北省精神卫生中心成瘾医学科, 河北 保定 071000
  • 收稿日期:2020-03-10 出版日期:2020-06-25 发布日期:2020-06-25
  • 通讯作者: 曹志然(1963— ),女,河北景县人,教授,硕士,硕士生导师,主要从事免疫药理学研究。E-mail: caozhiran@163.com
  • 作者简介:韩笑(1982— ),女,河北保定人,主治医师,在读硕士,主要从事临床精神病学研究。 E-mail: 67332837@qq.com
  • 基金资助:
    河北省2017年政府资助临床医学优秀人才培养和基础课题研究项目[冀财社(2017)46号]

  • Received:2020-03-10 Online:2020-06-25 Published:2020-06-25

摘要: 目的 探讨艾司西酞普兰合并托吡酯对男性酒依赖患者伴有焦虑抑郁的临床疗效、安全性及对复饮的影响。方法 采用了随机、对照的临床试验设计,把入组的患者分成艾司西酞普兰合并托吡酯治疗组(协同用药组)和单用艾司西酞普兰治疗组(单一用药组)。共治疗了12周,治疗前后分别采用了汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、用药后出现的不良反应量表(TESS)、可视渴求量表(VAS)等评估患者的临床效果及安全性。结果 2组HAMA、HAMD评分在治疗后4周末、8周末与治疗前比较差异有统计学意义(P<0.05)。随着治疗时间的延长2组VAS评分均逐渐下降,协同用药组渴求程度下降更为明显(P<0.05);协同用药组在随访6个月时复饮率低于单一用药组,差异有统计学意义(χ2=11.009,P=0.001<0.05);2组用药后不良反应发生率的差异无统计学意义(P>0.05)。结论 对伴焦虑抑郁症状的酒依赖患者,艾司西酞普兰合并托吡酯治疗焦虑、抑郁症状的疗效与单用艾司西酞普兰相当,但减少对酒的渴求优于单用艾司西酞普兰,且患者有更低的复饮率。2种治疗方案的不良反应相当。

关键词: 酒依赖, 托吡酯, 艾司西酞普兰, 焦虑, 抑郁, 复饮率

Abstract: Objective To investigate the clinical efficacy and safety of escitalopram combined with topiramate on male alcohol dependence with anxiety and depression,and the effect on the rate of relapse. Methods A randomized, controlled clinical trial design was used to randomly divide patients into escitalopram combined with topiramate treatment group(co-administration group)and escitalopram treatment group(single-treatment group). The comcourse of treatment was 12 weeks.Before and after treatment, the Hamilton Depression Scale(HAMD), Hamilton Anxiety Scale(HAMA), Symptom Scale(TESS), Visual Analogue Scale(VAS), etc. were used to evaluate the clinical efficacy of patients and safety. Results The HAMA and HAMD scores of the two groups were significantly different at the 4th and 8th weekends after treatment compared with before treatment(P<0.05). With the extension of treatment, the VAS scores of the two groups gradually decreased, and the degree of craving for alcohol in co-administration group was more obvious.Compared with the single-treatment group, the difference was statistically significant(P<0.05). The re-drinking rate of the co-administration group was lower than that of the single-treatment group at 6 months of follow-up, and the difference was statistically significant(χ2=11.009, P=0.001<0.05). The difference in the incidence of adverse reactions between the two groups was not statistically significant(P>0.05). Conclusion For the alcohol-dependent patients with anxiety and depression, the effect between esitalopram combined with topiramate and esitalopram alone treating anxiety and depression have no statistical difference, but the effect decreasing thirst for alcohol of esitalopram combined with topiramate is better than esitalopram alone, and the patients of esitalopram combined with topiramate have a lower rate of recidivism. The adverse effects of the two treatments are comparable.

Key words: alcohol dependence, topiramate, escitalopram, anxiety, depression, relapse rate

中图分类号: